Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz’s Biosimilar Filing Is Culmination Of Paradigm Shift In FDA Drug Review

Executive Summary

FDA clinical reviewers moved from traditional “new drug” review mode to determining the evidence needed to demonstrate a follow-on product is highly similar to the reference biologic, Sandoz exec says, describing firm’s interactions with FDA on its filgrastim 351(k) application.

You may also be interested in...



Sandoz Makes First Biosimilar Review Look Easy; Will Future Sponsors Be As Lucky?

Oncologic Drugs Advisory Committee’s unanimous endorsement of Neupogen biosimilar amounted to a slam dunk, but other sponsors with more complex biologics and less foreign marketing experience may face greater skepticism from FDA and its experts.

EU Data Helps Sandoz’s U.S. Clinical Program For Filgrastim

Because FDA agreed data comparing Sandoz’s filgrastim to EU-approved Neupogen could serve as bridge for comparisons to U.S.-approved Neupogen, firm only needed two additional studies for its biosimilar application.

Apotex Biosimilar Goes To FDA, But May Enter Crowded Market

Pegfilgrastim product, a collaboration with the Indian firm Intas, may have to compete with multiple filgrastim products, along with its reference biologic, Amgen’s Neulasta.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel